Steven A. King, MD, MS

June 20, 2014

Three new opioid analgesics that purport to offer benefits that current products lack come with marketing messages that ring both contradictory and redundant.

May 15, 2014

Controversy around FDA approval of an extended-release formulation of the opioid hydrocodone includes well-founded concerns about abuse but also exposes enduring ignorance about opioid analgesics in general.

March 26, 2014

Pain may be an ongoing problem even after successful treatment for cancer; effective pain management, however, may be overlooked.

November 14, 2013

The hydrocodone/acetaminophen combination is moved to Schedule II from III while single-agent extended-release hydrodocone is approved without a tamper-resistant mechanism.

October 23, 2013

The use of general anesthesia to speed opioid detox without the discomforts of withdrawal has no scientific support.

September 14, 2013

New opioid labeling restricts the type of patient who should be prescribed long-acting/extended release formulations.

August 30, 2013

Guideline recommendations are not only frequently being ignored, but the number of physicians not using them is growing.

August 05, 2013

The current study may help create new pathways for better understanding and developing more effective and more specific medications.

July 19, 2013

Rotating opioids can reduce the risk of developing tolerance to the analgesic effects of any single drug and of developing hyperalgesia.

June 10, 2013

"The patient's report" has long been considered the most valid measure of human pain. Can fMRI replace that?